Skip to Content

7 Results Found

  • Article
  • Open Access
4 Citations
6,949 Views
13 Pages

Fecal Zonulin as a Non-Invasive Marker of Intestinal Permeability: Findings from a Prospective Cohort Study

  • Naomi-Adina Ciurea,
  • Cristina Monica Pantea,
  • Paul Grama,
  • Irina-Bianca Kosovski and
  • Simona Bataga

25 August 2025

Background and Objectives: Metabolic dysfunction-associated steatotic liver disease (MASLD) is now widely acknowledged as belonging to the broader category of metabolic disorders, being closely associated with obesity, insulin resistance, and chronic...

(This article belongs to the Section Gastroenterology & Hepatology)
  • Article
  • Open Access
945 Views
19 Pages

An Invisible Early Steatosis Phenotype Defined for a Large Population-Based Cohort

  • Thierry Poynard,
  • Olivier Deckmyn,
  • Valentina Peta,
  • Raluca Pais and ,
  • Bernard Van Beers,
  • Laurent Castera,
  • Frederic Charlotte,
  • Valerie Paradis,
  • Pierre Bedossa and
  • Dominique Valla
  • + 5 authors+ 0 author

11 December 2025

Background: The current definition of metabolic dysfunction-associated steatotic liver disease (MASLD) relies on a classical assessment of steatosis via liver biopsy, with grades S0–S3 (5–100% fat) potentially underestimating low-grade st...

(This article belongs to the Section Endocrinology and Metabolism Research)
  • Article
  • Open Access
12 Citations
3,761 Views
15 Pages

Relationship between Adipokines and Cardiovascular Ultrasound Parameters in Metabolic-Dysfunction-Associated Fatty Liver Disease

  • Abdulrahman Ismaiel,
  • Mihail Spinu,
  • Livia Budisan,
  • Daniel-Corneliu Leucuta and ,
  • Stefan-Lucian Popa,
  • Bogdan Augustin Chis,
  • Ioana Berindan-Neagoe,
  • Dan Mircea Olinic and
  • Dan L. Dumitrascu
  • + 4 authors+ 0 author

7 November 2021

(1) Background: The role of adipokines such as adiponectin and visfatin in metabolic-dysfunction-associated fatty liver disease (MAFLD) and cardiovascular disease remains unclear. Therefore, we aim to assess serum adiponectin and visfatin levels in M...

(This article belongs to the Special Issue JCM-Advances in Cardiology)
  • Article
  • Open Access
6 Citations
4,753 Views
16 Pages

Anxiety and Depression in Metabolic-Dysfunction-Associated Fatty Liver Disease and Cardiovascular Risk

  • Abdulrahman Ismaiel,
  • Mihail Spinu,
  • Daniel-Corneliu Leucuta,
  • Stefan-Lucian Popa and ,
  • Bogdan Augustin Chis,
  • Mihaela Fadgyas Stanculete,
  • Dan Mircea Olinic and
  • Dan L. Dumitrascu
  • + 3 authors+ 0 author

28 April 2022

(1) Background: The relationship between anxiety and depression in metabolic-dysfunction-associated fatty liver disease (MAFLD) and cardiovascular (CV) risk remains uncertain. Therefore, we aimed to assess whether anxiety and depression are associate...

(This article belongs to the Special Issue Cardiovascular Disease: Risk Factors, Comorbidities, and Prevention)
  • Article
  • Open Access
7 Citations
2,692 Views
14 Pages

Effects of Achieving Sustained Virologic Response after Direct-Acting Antiviral Agents on Long-Term Liver Fibrosis in Diabetics vs. in Non-Diabetic Patients with Chronic Hepatitis C Infection

  • Marian-Sorin Popescu,
  • Dan-Mihai Firu,
  • Vlad Pădureanu,
  • Cristina Maria Mărginean and ,
  • Radu Mitruț,
  • Andreea Letitia Arsene,
  • Dragoș Nicolae Mărgăritescu,
  • Daniela Calina,
  • Anca Oana Docea and
  • Paul Mitruț
  • + 5 authors+ 0 author

Because of the prevalence of HCV worldwide as well as its undiagnosed population due to a lack of screening, HCV can be considered a modern pandemic disease. In 2016, the World Health Organization (WHO) set goals for HCV’s elimination that incl...

(This article belongs to the Special Issue Pathomechanisms of Disturbances Underlying Chronic Disorders)
  • Article
  • Open Access
634 Views
15 Pages

Metabolic and Lifestyle Profiles of Metabolic Dysfunction-Associated Steatotic Liver Disease in Romanian and Italian Adults

  • Naomi-Adina Ciurea,
  • Harshitha Shanmugam,
  • Cristina Monica Pantea,
  • Paul Grama and ,
  • Irina-Bianca Kosovski,
  • Simona Bataga,
  • Agostino Di Ciaula and
  • Piero Portincasa
  • + 3 authors+ 0 author

20 July 2026

Background: Metabolic dysfunction-associated steatotic liver disease (MASLD) represents the hepatic manifestation of systemic metabolic dysfunction and has become one of the leading causes of chronic liver disease worldwide. Although obesity is a maj...

(This article belongs to the Section Gastroenterology & Hepatology)
  • Article
  • Open Access
1,255 Views
18 Pages

4 February 2026

Metabolic Dysfunction-Associated Steato-Hepatitis (MASH) is a multiple-hit disease. Endotoxins, ethanol, and other metabolites of certain gut microbiota can reach the liver and accelerate inflammation and disease progression. Targeting ethanol-produc...